You can hardly rank CYC up there with CBA. With a junior company it's good to see what they've been up to and whether their revenue is increasing. Not providing a quarterly activities or cashflow report shows a lack of transparency and doesn't give the market any reason to buy, hence the SP drifts lower
Ann: Cyclopharm Signs First USA Contract for Technegas, page-37
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.00 |
Change
0.005(0.50%) |
Mkt cap ! $111.1M | |||
| Open | High | Low | Value | Volume |
| $1.00 | $1.04 | $1.00 | $215.2K | 211.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10089 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.04 | 3762 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| CYC (ASX) Chart |